Division of Hematology and Oncology, Department of Medicine, Stony Brook University Cancer Center, Stony Brook, New York 11794-9447, USA.
Cancer Invest. 2011 Aug;29(7):460-71. doi: 10.3109/07357907.2011.597815.
Novel agents to reduce angiogenesis by targeting vascular endothelial growth factor and other proangiogenic signaling pathways are being developed for advanced nonsmall cell lung cancer. Antibody-based therapies (e.g., aflibercept) and multitargeted tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, and BIBF 1120) are being evaluated in phase III clinical trials. Some antiangiogenic agents have demonstrated distinct profiles in producing a variety of nonhematologic toxicities, including bleeding/hemorrhage, venous and arterial thromboembolic events, gastrointestinal perforation, hypertension, and proteinuria. Elucidating the molecular basis of these toxicities may lead to clinical benefits by improving patient selection and allowing for the development of effective prevention and management strategies.
正在开发针对血管内皮生长因子和其他促血管生成信号通路的新型药物来治疗晚期非小细胞肺癌。基于抗体的治疗方法（如阿柏西普）和多靶点酪氨酸激酶抑制剂（如索拉非尼、舒尼替尼和 BIBF1120）正在进行 III 期临床试验。一些抗血管生成药物在产生多种非血液学毒性方面表现出不同的特征，包括出血/出血、静脉和动脉血栓栓塞事件、胃肠道穿孔、高血压和蛋白尿。阐明这些毒性的分子基础可能通过改善患者选择和开发有效的预防和管理策略，从而带来临床获益。
